Targeting faulty DNA repair mechanisms in advanced castration resistant prostate cancer can slow progression and potentially improve survival, paving the way for a new approach to treatment of the most common form of cancer ...
Sep 30, 2019
0
4
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with ...
Sep 30, 2019
0
15
New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic ...
Jun 24, 2019
0
0
Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN (National Clinical Trials Number 02489318), which evaluated the effectiveness and safety of a ...
Jun 3, 2019
0
10
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators ...
Feb 15, 2019
0
2
A translational research team led by the National University of Singapore (NUS) has harnessed CURATE.AI, a powerful artificial intelligence (AI) platform, to treat a patient with advanced cancer, completely halting disease ...
Sep 4, 2018
0
6
Researchers at the University of Oulu in Finland have discovered novel genes and mechanisms that can explain how a genomic variant in a single nucleotide polymorphism (SNP) rs11672691 influences prostate cancer aggressiveness. ...
Jul 20, 2018
0
4
The dark matter of the human genome may shed light on how the hormone androgen impacts prostate cancer.
May 28, 2018
0
50
Almost 48,000 men are diagnosed with prostate cancer in the UK every year. But questions are being asked of the tests used to diagnose these men, and how they might be improved.
May 10, 2018
0
16
Treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy. The results ...
Feb 8, 2018
0
3
